期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

常见肿瘤维持治疗的成功模式 被引量：8

Successful patterns of maintenance therapy in human common cancer
原文传递
导出
摘要 维持治疗已成为肿瘤治疗的有效策略，分为持续维持治疗和转换维持治疗，其经典模式为节拍化疗。维持治疗在非小细胞肺癌、乳腺癌、结直肠癌和卵巢癌中的成功应用显示了其潜在价值。 Maintenance therapy is an important strategy for cancer treatment, which mainly include continuation maintenance therapy and switch maintenance therapy, with a classical model of metronomic chemotherapy. Maintenance therapy can be an effective treatment option for patients with non-small cell lung cancer, breast cancer, eolorectal cancer and ovarian cancer.
作者 张百红 岳红云
机构地区 兰州军区兰州总医院肿瘤科 兰州军区兰州总医院眼科
出处 《国际肿瘤学杂志》 CAS 2014年第9期655-658,共4页 Journal of International Oncology
基金 基金项目：甘肃省自然科学基金（1308RJZA181）
关键词 肿瘤 维持化疗 多中心研究 Neoplasms Maintenance chemotherapy Muhicenter studies
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Gerber DE, Schiller JH. Maintenance chemotherapy for advanced nonsmallcell lung cancer: new life for an old idea[J].J Clin Oncol.2013, 31(8):1009-1020.
  • 2André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in lowincome and middleincome countries?[J]. Lancet Oncol, 2013, 14(6): e239-248.
  • 3Loven D, Hasnis E, Bertolini F, et al. Lowdose metronomicchemotherapy: from past experience to new paradigms in the treatment of cancer[J].Drug Discov Today.2013, 18(34):193-201.
  • 4Granovetter M. Maintenance therapy improves survival of NSCLC patients[J]. Lancet Oncol, 2013, 14(9): e347.
  • 5PazAres L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial[J].Lancet Oncol.2012, 13(3):247-255.
  • 6PazAres LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer[J].J Clin Oncol.2013, 31(23):2895-2902.
  • 7Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmallcell lung cancer: AVAPERL (MO22089)[J].J Clin Oncol.2013, 31(24):3004-3011.
  • 8Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced nonsmallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3EMCJMEN): results from a randomised, doubleblind, phase 3 study[J].Lancet Oncol.2012, 13(3):292-299.
  • 9Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous nonsmallcell lung cancer[J].J Clin Oncol.2013, 31(34):4349-4357.
  • 10Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage Ⅲ nonsmallcell lung cancer (START): a randomised, doubleblind, phase 3 trial[J].Lancet Oncol.2014, 15(1):59-68.

同被引文献132

引证文献8

二级引证文献31

国际肿瘤学杂志
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部